1. Home
  2. KLC vs AGIO Comparison

KLC vs AGIO Comparison

Compare KLC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLC
  • AGIO
  • Stock Information
  • Founded
  • KLC 1969
  • AGIO 2007
  • Country
  • KLC United States
  • AGIO United States
  • Employees
  • KLC N/A
  • AGIO N/A
  • Industry
  • KLC
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • KLC
  • AGIO Health Care
  • Exchange
  • KLC NYSE
  • AGIO Nasdaq
  • Market Cap
  • KLC 1.3B
  • AGIO 1.4B
  • IPO Year
  • KLC 2024
  • AGIO 2013
  • Fundamental
  • Price
  • KLC $11.26
  • AGIO $27.66
  • Analyst Decision
  • KLC Buy
  • AGIO Buy
  • Analyst Count
  • KLC 8
  • AGIO 8
  • Target Price
  • KLC $27.88
  • AGIO $56.57
  • AVG Volume (30 Days)
  • KLC 1.1M
  • AGIO 745.1K
  • Earning Date
  • KLC 05-14-2025
  • AGIO 05-01-2025
  • Dividend Yield
  • KLC N/A
  • AGIO N/A
  • EPS Growth
  • KLC N/A
  • AGIO N/A
  • EPS
  • KLC N/A
  • AGIO 11.64
  • Revenue
  • KLC $2,663,035,000.00
  • AGIO $36,498,000.00
  • Revenue This Year
  • KLC $6.50
  • AGIO $41.13
  • Revenue Next Year
  • KLC $4.90
  • AGIO $234.96
  • P/E Ratio
  • KLC N/A
  • AGIO $2.38
  • Revenue Growth
  • KLC 6.09
  • AGIO 36.07
  • 52 Week Low
  • KLC $10.31
  • AGIO $23.42
  • 52 Week High
  • KLC $29.89
  • AGIO $62.58
  • Technical
  • Relative Strength Index (RSI)
  • KLC N/A
  • AGIO 44.94
  • Support Level
  • KLC N/A
  • AGIO $26.87
  • Resistance Level
  • KLC N/A
  • AGIO $28.24
  • Average True Range (ATR)
  • KLC 0.00
  • AGIO 1.94
  • MACD
  • KLC 0.00
  • AGIO 0.22
  • Stochastic Oscillator
  • KLC 0.00
  • AGIO 66.15

About KLC KINDERCARE LEARNING COMPANIES INC

KinderCare Learning Companies Inc is a private provider of early childhood education and care services (ECE) in the United States. It serves children ranging from 6 weeks to 12 years of age across its market footprint of around 1,480 early childhood education centers with a capacity of more than 194,000 children and contracts for more than 650 before- and after-school sites located in 40 states and the District of Columbia. Its segment derives revenue from providing early childhood education and care services at centers and before- and after-school sites.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: